1. Evaluation of unfractionated heparin versus low‐molecular‐weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. (15th November 2018) Authors: Van Matre, E. T.; Reynolds, P. M.; MacLaren, R.; Mueller, S. W.; Wright, G. C.; Moss, M.; Burnham, E. L.; Ho, P. M.; Vandivier, R. W.; Kiser, T. H. Journal: Journal of thrombosis and haemostasis Issue: Volume 16:Number 12(2018) Page Start: 2492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES. (2nd June 2020) Authors: Tesser, J.; Wright, G. C.; Strand, V.; Kaine, J.; Maslova, K.; St John, G.; Ford, K.; Praestgaard, A.; Choy, E. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS. (2nd June 2020) Authors: Gottenberg, J. E.; Buch, M. H.; Caporali, R.; Wright, G. C.; Takeuchi, T.; Kalunian, K.; Pechonkina, A.; Guo, Y.; Rao, S.; Tan, Y.; Besuyen, R.; Genovese, M. C. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗